Archive for 'Tag Archives: 'Cell therapy''

Bone Therapeutics raises EUR 32.2 million through IPO

Bone Therapeutics raises EUR 32.2 million through IPO

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises EUR 32.2 million in a 2.5x oversubscribed successful IPO on Brussels and Paris Euronext [...]

Synolyne Pharma raises its capital by € 3.3 million and sets off to market its product against degenerative osteoarthritis

Synolyne Pharma raises its capital by € 3.3 million and sets off to market its product against degenerative osteoarthritis

  Updating on a story from 2012, the spin-off of ULg, Synolyne Pharma has raised € 3,3 million to pursue the development of its treatment against degenerative osteoarthritis and in addition, sign an agreement with KitoZyme [...]

Belgo-American partnership between Promethera Biosciences and EMD Millipore to develop pre-clinical liver pharmaco-toxicological testing assay

Belgo-American partnership between Promethera Biosciences and EMD Millipore to develop pre-clinical liver pharmaco-toxicological testing assay

  The recent Belgo-American partnership between Promethera® Biosciences (Mont-Saint-Guibert, Belgium), and EMD Millipore (Billerica, MA USA) to develop an improved ready-to-use microfluidic perfusion liver assay, is BioWin’s latest ‘Success Story’. The initiative behind this strategic project [...]

Opening Bell Ceremony kicks off Advanced Therapies Investor Day (Brussels)

Opening Bell Ceremony kicks off Advanced Therapies Investor Day (Brussels)

The first European Advanced Therapies Investor Day began with the sound of  the “opening bell” of the Euronext stock market (Brussels) resonating the potential of the rapidly expanding sector of advanced therapies. Watch ceremony For the [...]

Marie Curie research grant awards €3.8 million in funding to Bone Therapeutics (Gosselies, Belgium) and partners

Marie Curie research grant awards €3.8 million in funding to Bone Therapeutics (Gosselies, Belgium) and partners

As part of an expert pan-European consortium* BONE THERAPEUTICS has been awarded a share of the highly competitive Marie Curie grant1 in the amount of €3.8 million. The grant will fund a four-year project entitled BIO-INSPIRE [...]

Cardio3 BioSciences raises € 4.0 million from the Walloon Region (non-dilutive funding)

Cardio3 BioSciences raises € 4.0 million from the Walloon Region (non-dilutive funding)

Cardio3 BioSciences SA has announced that it has received €4.0 million of non-dilutive funding from the Walloon Region through the conclusion of a new recoverable cash advance (RCA) granted for an amount of €2.5 million and [...]

Cardio3 BioSciences named Trends-Tendances Business Tour 2013 Most Innovative Company for Brabant Walloon

Cardio3 BioSciences named Trends-Tendances Business Tour 2013 Most Innovative Company for Brabant Walloon

Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) has been named winner of the Trends-Tendances Business Tour 2013 Award in the “Innovation” category for the Brabant Walloon region.  The Business Tour showcases three companies in each province in the country in [...]

Public-private partnership leads to unique Walloon Cell Therapy Platform

Public-private partnership leads to unique Walloon Cell Therapy Platform

As the foundation for the new Walloon Cell Therapy Platform* begins to set in Gosselies, Belgium an exciting new development for Wallonia gets underway. The platform, unique in this sector, will provide Wallonia with a new [...]

Cardio3 BioSciences to consider launching an IPO on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences to consider launching an IPO on NYSE Euronext Brussels and NYSE Euronext Paris

Latest news from  Mont-Saint-Guibert, Belgium – Cardio3 BioSciences SA has recently announced that it is considering raising new funds through an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris. This is an update to the [...]

Cardio3 BioSciences’ publishes Phase II trial results for stem cell therapy treatment in the JACC and increases its equity by €19 million.

Cardio3 BioSciences’ publishes Phase II trial results for stem cell therapy treatment in the JACC and increases its equity by €19 million.

Two exciting new announcements have recently been made by Belgian-based biotechnology company Cardio3 BioSciences(Mont-Saint Guibert, Wallonia). In early April the company announced the publication of Phase II trial results for stem cell therapy C-Cure® in the [...]